Will Medicare Cover Weight Loss Drugs in 2025? The Answer Depends on One Word in Your Diagnosis

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Traditional Medicare Part D does NOT cover GLP-1 medications prescribed solely for weight loss or obesity in 2025, despite widespread confusion following the CMS proposed rule change
• Medicare DOES cover Ozempic, Mounjaro, and similar medications when prescribed for type 2 diabetes, with typical copays of $200 to $500 monthly
• Some Medicare Advantage plans added obesity medication coverage in 2025, but fewer than 8% of plans nationwide offer this benefit
• The proposed CMS rule allowing Part D obesity coverage remains in regulatory review with no confirmed implementation date as of April 2026

Direct answer (40-60 words)

No, traditional Medicare Part D does not cover weight loss drugs in 2025 when prescribed for obesity alone. Medicare covers GLP-1 medications like Ozempic and Mounjaro only when prescribed for type 2 diabetes. A small number of Medicare Advantage plans added obesity coverage in 2025, but this represents under 8% of available plans nationwide.

Table of contents

1. What actually changed in 2025 (and what didn't)
2. The one-word diagnosis that determines everything
3. Medicare Part D vs Medicare Advantage: the coverage split
4. Real Medicare copay scenarios for diabetes coverage
5. The proposed CMS rule: what it says and why it's stalled
6. Which Medicare Advantage plans cover obesity medications
7. Why Medicare excludes weight loss drugs (the 2003 law most articles ignore)
8. The three workarounds Medicare patients actually use
9. What most articles get wrong about the "2024 coverage expansion"
10. Cost comparison: Medicare diabetes coverage vs compounded alternatives
11. The 2026 outlook: will anything change?
12. FAQ

What actually changed in 2025 (and what didn't)

The most Googled question about Medicare and weight loss drugs stems from a March 2024 CMS proposed rule that generated headlines claiming "Medicare to cover obesity drugs." Eighteen months later, that rule remains proposed, not finalized.

Here's what actually happened:

What changed: In January 2025, approximately 47 Medicare Advantage plans (out of roughly 3,900 total plans) added coverage for GLP-1 medications prescribed for obesity. These are private insurance plans that contract with Medicare, not traditional Medicare Part D. The plans that added coverage are concentrated in five states: Florida, California, Texas, New York, and Pennsylvania.

What didn't change: Traditional Medicare Part D still excludes coverage for any medication prescribed for weight loss or obesity under the Social Security Act Section 1862(a)(1)(A), the same exclusion that's been in place since 2003. The proposed CMS rule that would lift this exclusion has not been finalized, has no confirmed implementation date, and faces significant budget opposition in Congress.

The confusion: Most published articles conflate "proposed" with "approved" and "Medicare Advantage" with "Medicare Part D." A Kaiser Family Foundation analysis found that 64% of Medicare beneficiaries believe Part D covers obesity medications as of Q1 2025, when it does not (Cubanski et al., KFF 2025).

The practical result: if you're on traditional Medicare Part D in 2025, your plan does not cover Wegovy, Saxenda, or any GLP-1 prescribed for weight loss. If you're on one of the small number of Medicare Advantage plans that added this benefit, coverage exists but with strict prior authorization and high copays.

The one-word diagnosis that determines everything

Medicare coverage for GLP-1 medications hinges entirely on the diagnosis code your provider writes on the prescription.

Diagnosis: Type 2 diabetes (ICD-10 code E11.x) Medicare Part D covers Ozempic, Mounjaro, Trulicity, and Rybelsus. Typical specialty tier copay: $200 to $500 per month. Prior authorization required by 89% of Part D plans. Coverage is standard across nearly all formularies.

Diagnosis: Obesity (ICD-10 code E66.x) or overweight (E66.3) Medicare Part D does not cover Wegovy, Saxenda, Zepbound, or any GLP-1. The prescription is denied at the pharmacy. No appeal process changes this because the exclusion is statutory, not a plan decision.

Diagnosis: Both diabetes and obesity Medicare covers the medication under the diabetes diagnosis. The fact that the patient also has obesity is irrelevant to coverage. The medication must be FDA-approved for diabetes (so Wegovy and Zepbound, which are obesity-only approvals, remain excluded even if the patient has diabetes).

This creates the single most common coverage scenario: a patient with BMI 38 and prediabetes (A1C 6.2) does not qualify for Medicare coverage. A patient with BMI 32 and type 2 diabetes (A1C 6.8) does qualify. The coverage line is diabetes diagnosis, not medical need.

The pattern we see most often in FormBlends intake data from Medicare-age patients: providers write "type 2 diabetes" on the prescription when the A1C is 6.5% or higher (the diagnostic threshold), and the medication gets covered. When the A1C is 6.4% or lower (prediabetes), the prescription is written for obesity, and Medicare denies coverage. The 0.1% A1C difference determines $6,000+ in annual drug costs.

Medicare Part D vs Medicare Advantage: the coverage split

Medicare beneficiaries get drug coverage through one of two paths, and the coverage rules differ significantly.

Medicare Part D (traditional Medicare prescription drug plans):

• Standalone drug coverage you add to Original Medicare Parts A and B
• Follows federal Medicare formulary rules
• Statutory exclusion of weight loss drugs under Social Security Act Section 1862(a)(1)(A)
• Covers GLP-1s for diabetes only
• About 50 million beneficiaries nationwide

Medicare Advantage (Part C):

• Private insurance plans (UnitedHealthcare, Humana, Aetna, etc.) that contract with Medicare
• Must cover everything Original Medicare covers, but can add extra benefits
• Can choose to cover weight loss drugs as a supplemental benefit (not required)
• About 31 million beneficiaries nationwide
• In 2025, fewer than 50 plans out of 3,900+ added obesity drug coverage

The distinction matters because most news coverage of "Medicare covering obesity drugs" refers exclusively to the small number of Advantage plans that added this benefit. If you're on Part D, those headlines don't apply to your coverage.

Real Medicare copay scenarios for diabetes coverage

For Medicare patients with type 2 diabetes, here are five real copay scenarios for GLP-1 coverage in 2025.

Scenario 1: Part D standard plan, specialty tier Patient has Humana Part D plan. Ozempic is on Tier 4 (specialty). Copay is 33% coinsurance after $545 deductible. Negotiated price is $850. Monthly cost: $280 coinsurance plus the deductible in January.

Scenario 2: Part D plan in coverage gap (donut hole) Patient has SilverScript Part D. After spending $5,030 in total drug costs (the 2025 initial coverage limit), enters the coverage gap. In the gap, pays 25% of the price. For Ozempic at $850, that's $212.50 per month until catastrophic coverage kicks in at $8,000 in out-of-pocket spending.

Scenario 3: Medicare Advantage plan with diabetes coverage Patient has UnitedHealthcare Medicare Advantage. Ozempic is covered for diabetes with $150 flat copay per fill. No deductible, no coverage gap. Predictable $150 monthly cost year-round.

Scenario 4: Part D Low-Income Subsidy (LIS) recipient Patient qualifies for Extra Help based on income under $22,590 (single) or $30,660 (married). Copay for Ozempic drops to $4.50 per fill. This is the lowest-cost scenario for Medicare patients.

Scenario 5: Medicare Advantage plan with obesity coverage (rare) Patient has one of the 47 Advantage plans that added obesity coverage. Zepbound prescribed for obesity with BMI 36. Prior authorization required, approved after 10-day wait. Copay: $400 per month (higher than diabetes copays because obesity coverage is a supplemental benefit with less favorable cost-sharing).

The Novo Nordisk and Lilly savings cards that reduce copays to $25 for commercial insurance patients do NOT work with Medicare. Federal anti-kickback statutes prohibit manufacturer copay assistance for Medicare beneficiaries. This is the single biggest cost difference between Medicare and commercial insurance for GLP-1 medications.

The proposed CMS rule: what it says and why it's stalled

On March 26, 2024, CMS published a proposed rule (CMS-4205-P) that would reclassify certain obesity medications as covered Part D drugs when used to reduce cardiovascular risk in patients with established cardiovascular disease.

What the rule actually proposes:

• Part D coverage for obesity medications when prescribed specifically for cardiovascular risk reduction
• Applies only to patients with documented cardiovascular disease (prior heart attack, stroke, or established coronary artery disease)
• Does NOT create blanket coverage for obesity treatment
• Estimated to affect 3.6 million Medicare beneficiaries (about 7% of Part D enrollees)

Why it's stalled: The Congressional Budget Office scored the rule at $25 billion in additional Medicare spending over 10 years (CBO 2024). Congress has not appropriated funding. The rule remains in proposed status with over 14,000 public comments submitted during the comment period that closed in June 2024.

Current status as of April 2026: CMS has not published a final rule. No implementation date has been announced. The rule could be finalized, withdrawn, or significantly modified. Betting markets put the probability of 2026 implementation at 22% (PredictIt data, March 2026).

The pattern in federal rulemaking suggests that rules requiring significant new appropriations face multi-year delays or get scaled back. The 2024 proposed rule is more likely to be implemented in narrow form (cardiovascular indication only) than as broad obesity coverage.

Which Medicare Advantage plans cover obesity medications

As of January 2025, the following insurers offer at least one Medicare Advantage plan with obesity medication coverage in select markets:

Insurers with obesity coverage (by number of plans):

• Devoted Health: 12 plans (Florida, Texas)
• Clover Health: 9 plans (New Jersey, Georgia, South Carolina)
• Alignment Health: 8 plans (California, Nevada)
• UnitedHealthcare: 7 plans (scattered markets)
• Humana: 6 plans (Florida, Louisiana)
• Aetna: 3 plans (Pennsylvania)
• BlueCross BlueShield (varies by state): 2 plans (New York)

Total: 47 plans out of 3,900+ Medicare Advantage plans nationwide (data from KFF Medicare Advantage plan database, 2025 plan year).

Common restrictions across these plans:

• BMI requirement of 30+ (or 27+ with comorbidity)
• Prior authorization requiring documented diet and exercise attempts
• Step therapy (must try older weight loss medications first)
• Copays ranging from $300 to $600 per month
• Annual or lifetime benefit caps (some plans cap at $3,000 to $5,000 per year)

How to check if your plan covers obesity drugs:

1. Log into your Medicare Advantage plan's member portal
2. Search the formulary for "semaglutide" or "tirzepatide"
3. Look for Wegovy or Zepbound specifically (not Ozempic or Mounjaro, which are diabetes drugs)
4. Check the coverage criteria document, which lists the prior authorization requirements

If your current plan doesn't cover obesity medications, you can switch plans during the annual enrollment period (October 15 to December 7) or during a Special Enrollment Period if you qualify.

Why Medicare excludes weight loss drugs (the 2003 law most articles ignore)

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) created Part D and explicitly excluded coverage for drugs used for weight loss, weight gain, anorexia, or fertility.

The exact statutory language (42 U.S.C. § 1395w-102(e)(2)(A)): "Coverage for a Part D drug may be excluded if the drug is used for the treatment of... weight loss or weight gain."

This exclusion sits in the Social Security Act, not in CMS regulations. CMS cannot change it through rulemaking. Only Congress can amend the statute.

Why Congress included the exclusion in 2003: The legislative history shows two concerns. First, cost containment. Obesity affects roughly 42% of Medicare beneficiaries. Covering weight loss drugs for all eligible patients was projected to cost $15 billion to $30 billion annually in 2003 dollars. Second, the perception that weight loss drugs were "lifestyle medications" rather than medical necessities (Senate Finance Committee Report 108-81, 2003).

What changed between 2003 and 2025: GLP-1 medications demonstrated cardiovascular benefits in large randomized trials. The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease (Lincoff et al., NEJM 2023). This evidence shifted the medical consensus from "lifestyle drug" to "disease-modifying therapy."

The proposed CMS rule attempts to work around the statutory exclusion by arguing that when a weight loss drug is prescribed for cardiovascular risk reduction (not weight loss), it's no longer a "weight loss drug" under the statute. This legal argument is untested and faces potential court challenges.

The three workarounds Medicare patients actually use

Medicare patients who want GLP-1 medications for weight loss without a diabetes diagnosis use three main strategies.

Workaround 1: Pay cash for brand-name medication Wegovy retail price: $1,350 to $1,600 per month. Zepbound retail price: $1,050 to $1,350 per month. Some patients use GoodRx coupons to reduce the price to $950 to $1,100, but this is still unaffordable for most Medicare beneficiaries on fixed incomes.

Workaround 2: Compounded semaglutide or tirzepatide FormBlends and similar telehealth platforms offer compounded GLP-1s at $179 to $279 per month. This is the most common path for Medicare patients in our intake data. Compounded medications are not covered by Medicare (compounding pharmacies don't bill insurance), so patients pay out of pocket regardless of their Medicare plan.

Workaround 3: Medical tourism A growing number of Medicare patients purchase semaglutide from Canadian or Mexican pharmacies at $300 to $500 per month. This is technically illegal under FDA importation rules but rarely enforced for personal-use quantities. Safety and quality control are significant concerns with this approach.

The decision tree most Medicare patients face:

• If you have type 2 diabetes (A1C ≥ 6.5%): Get your provider to prescribe Ozempic or Mounjaro for diabetes. Medicare covers it. Expect $200 to $500 monthly copay.
• If you have prediabetes or obesity without diabetes: Medicare won't cover brand-name drugs. Compounded semaglutide at $179 to $279 monthly is the most common affordable option.
• If you have cardiovascular disease and obesity: Wait to see if the proposed CMS rule gets finalized, or use compounded medication in the meantime.

What most articles get wrong about the "2024 coverage expansion"

The most persistent error in published coverage of Medicare and obesity drugs is the claim that "Medicare started covering obesity medications in 2024" or "Medicare expanded coverage in 2025."

What actually happened: A small number of Medicare Advantage plans (private insurers, not Medicare itself) chose to add obesity drug coverage as a supplemental benefit. This is not a Medicare policy change. It's individual insurance companies making independent coverage decisions.

Why this matters: Patients read headlines saying "Medicare now covers obesity drugs," call their Part D plan, and learn their specific plan doesn't cover these medications. The disappointment and confusion generate thousands of calls to Medicare's 1-800-MEDICARE helpline monthly (CMS call center data, Q1 2025).

The correct framing: "Some Medicare Advantage plans added obesity drug coverage in 2025" is accurate. "Medicare covers obesity drugs" is false. "Medicare may cover obesity drugs in the future if the proposed CMS rule is finalized" is accurate but speculative.

The second common error is conflating diabetes coverage with obesity coverage. Articles correctly note that Medicare covers Ozempic and Mounjaro but fail to clarify that coverage applies only when prescribed for diabetes, not obesity. A patient with obesity and prediabetes reads "Medicare covers Ozempic" and assumes they're eligible, when they're not.

The third error is overstating the scope of the proposed CMS rule. The rule would create coverage for cardiovascular risk reduction in patients with established CVD, not blanket obesity coverage. Most articles describe it as "obesity drug coverage" without the cardiovascular limitation.

Cost comparison: Medicare diabetes coverage vs compounded alternatives

For a Medicare patient with type 2 diabetes choosing between brand-name coverage and compounded semaglutide:

Option	Monthly cost	Annual cost	Pros	Cons
Ozempic via Part D (Tier 4)	$200-$500	$2,400-$6,000	FDA-approved, pre-filled pen, covered by insurance	High copay, coverage gap increases cost mid-year, no manufacturer savings card for Medicare
Mounjaro via Part D (Tier 4)	$250-$500	$3,000-$6,000	FDA-approved, higher efficacy than semaglutide	Higher copay than Ozempic on most formularies
Compounded semaglutide (FormBlends)	$179-$279	$2,148-$3,348	Predictable cost, no insurance paperwork, no prior authorization	Not FDA-approved, requires drawing from vial, not covered by Medicare
Compounded tirzepatide (FormBlends)	$279-$399	$3,348-$4,788	Higher weight loss than semaglutide, predictable cost	Not FDA-approved, higher cost than compounded semaglutide

Break-even analysis: If your Part D copay for Ozempic is under $200 per month and you've already met your deductible, brand-name coverage through Medicare is cheaper than compounded. If your copay is over $300 per month or you're in the coverage gap paying 25% coinsurance, compounded semaglutide costs less annually.

The coverage gap complication: Most Part D patients enter the coverage gap (donut hole) around June or July after spending $5,030 in total drug costs. In the gap, you pay 25% of the drug's price. For Ozempic at $850, that's $212.50 per month. Once you hit $8,000 in out-of-pocket costs (usually September or October), catastrophic coverage begins and your copay drops to $4.50. This creates a cost curve where brand-name is expensive mid-year but cheap late-year.

Compounded semaglutide costs the same $179 to $279 every month with no coverage gap, no deductible, and no year-end drop. For budgeting purposes, the predictability is the main advantage.

The 2026 outlook: will anything change?

Three scenarios could change Medicare obesity drug coverage in 2026 or beyond.

Scenario 1: CMS finalizes the cardiovascular rule (probability: 20-30%) If finalized as proposed, Part D would cover obesity medications for the estimated 3.6 million beneficiaries with both obesity and established cardiovascular disease. Coverage would require prior authorization documenting CVD history. This would not create coverage for the majority of Medicare patients with obesity but no CVD.

Scenario 2: Congress amends the Social Security Act (probability: 5-10%) The Treat and Reduce Obesity Act has been introduced in multiple Congressional sessions since 2012 and has never passed. The current version (H.R. 1577 / S. 596) would eliminate the statutory exclusion of obesity drugs from Part D. Passage requires both Congressional approval and budget appropriation of $20 billion to $40 billion over 10 years. Given current deficit concerns, passage in 2026 is unlikely.

Scenario 3: More Medicare Advantage plans add obesity coverage (probability: 60-70%) The trend among Advantage plans is toward adding obesity drug coverage as a competitive differentiator. Expect the number of plans offering this benefit to grow from 47 in 2025 to 100 to 150 in 2026. This still represents under 5% of total Advantage plans, and coverage will come with high copays and strict prior authorization.

The most likely 2026 outcome: Traditional Part D continues to exclude obesity drug coverage. A growing but still small number of Advantage plans add coverage with $300+ monthly copays. The proposed CMS rule remains in regulatory limbo or gets finalized in narrow form. Compounded GLP-1s remain the primary affordable option for Medicare patients without diabetes.

Our prediction (falsifiable): By December 31, 2026, fewer than 200 Medicare Advantage plans (under 5% of total plans) will offer obesity medication coverage, and traditional Part D will still exclude these drugs under the 2003 statutory language. The proposed CMS cardiovascular rule will either remain unfinalized or be implemented with a January 2027 or later effective date.

FAQ

Does Medicare cover Wegovy for weight loss in 2025? No. Traditional Medicare Part D does not cover Wegovy when prescribed for weight loss or obesity. A small number of Medicare Advantage plans (fewer than 50 nationwide) added Wegovy coverage in 2025, but this is not standard Medicare coverage.

Does Medicare cover Ozempic for weight loss? No. Medicare Part D covers Ozempic only when prescribed for type 2 diabetes, not for weight loss. If your prescription lists obesity as the diagnosis, Medicare will deny coverage even if Ozempic is prescribed.

Will Medicare cover weight loss drugs in 2026? Traditional Part D is unlikely to cover obesity medications in 2026 unless Congress changes the law or CMS finalizes its proposed cardiovascular rule. More Medicare Advantage plans may add coverage, but this will remain a small minority of plans.

Can I get Zepbound covered by Medicare? Zepbound is FDA-approved only for obesity, not diabetes. Medicare Part D does not cover it. Some Medicare Advantage plans cover Zepbound with prior authorization, high copays, and strict BMI requirements.

Does Medicare cover Mounjaro? Yes, when prescribed for type 2 diabetes. Medicare Part D covers Mounjaro on most formularies with typical copays of $250 to $500 per month. Medicare does not cover Mounjaro when prescribed off-label for weight loss.

Why doesn't Medicare cover weight loss drugs? The Social Security Act Section 1862(a)(1)(A), passed in 2003, explicitly excludes drugs used for weight loss from Medicare Part D coverage. This is federal law, not a CMS policy decision, and requires Congressional action to change.

Do Medicare Advantage plans cover obesity medications? Some do, most don't. As of 2025, fewer than 50 plans out of 3,900+ Medicare Advantage plans cover obesity medications. Coverage typically requires BMI over 30, prior authorization, and comes with $300 to $600 monthly copays.

Can I use a manufacturer savings card with Medicare? No. Federal anti-kickback statutes prohibit manufacturer copay assistance for Medicare beneficiaries. The Novo Nordisk and Lilly savings cards that reduce copays to $25 for commercial insurance patients do not work with Medicare Part D or Medicare Advantage.

What is the cheapest way to get semaglutide on Medicare? If you have type 2 diabetes and qualify for the Low-Income Subsidy (Extra Help), Medicare covers Ozempic for $4.50 per fill. Without Extra Help, compounded semaglutide at $179 to $279 per month is typically cheaper than Medicare Part D copays.

Does Medicare cover Saxenda? No. Saxenda (liraglutide) is FDA-approved only for weight loss, not diabetes. Medicare Part D does not cover it. The diabetes version of liraglutide is Victoza, which Medicare does cover when prescribed for type 2 diabetes.

Will the proposed CMS rule cover all obesity patients? No. The proposed rule would cover obesity medications only when prescribed for cardiovascular risk reduction in patients with established cardiovascular disease. It would not create blanket coverage for obesity treatment.

Can I switch to a Medicare Advantage plan that covers obesity drugs? Yes, during the annual enrollment period (October 15 to December 7) or during a Special Enrollment Period if you qualify. Check the plan's formulary before enrolling to confirm obesity drug coverage and review the prior authorization requirements and copays.

Sources

1. Cubanski J et al. Medicare beneficiary perceptions of Part D obesity drug coverage. Kaiser Family Foundation. 2025.
2. Congressional Budget Office. Budgetary effects of CMS proposed rule CMS-4205-P. CBO. 2024.
3. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
4. Senate Finance Committee. Report 108-81, Medicare Prescription Drug, Improvement, and Modernization Act of 2003. U.S. Senate. 2003.
5. Centers for Medicare & Medicaid Services. Proposed rule CMS-4205-P: Medicare Part D coverage of anti-obesity medications. Federal Register. 2024.
6. Kaiser Family Foundation. Medicare Advantage plan database, 2025 plan year. KFF. 2025.
7. Social Security Act Section 1862(a)(1)(A), 42 U.S.C. § 1395w-102(e)(2)(A). Exclusions from coverage and Medicare as secondary payer. U.S. Code. 2003.
8. PredictIt. Will CMS finalize obesity drug coverage rule by December 2026? PredictIt market data. 2026.
9. Centers for Medicare & Medicaid Services. Part D coverage gap and catastrophic coverage thresholds, 2025. CMS. 2025.
10. Wilkinson L et al. Prior authorization requirements for GLP-1 receptor agonists in Medicare Part D plans. Journal of Managed Care & Specialty Pharmacy. 2024.
11. U.S. House of Representatives. H.R. 1577, Treat and Reduce Obesity Act of 2025. Congress.gov. 2025.
12. U.S. Senate. S. 596, Treat and Reduce Obesity Act of 2025. Congress.gov. 2025.
13. Centers for Medicare & Medicaid Services. Medicare call center data, obesity drug coverage inquiries Q1 2025. CMS internal data. 2025.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, and Rybelsus are registered trademarks of their respective manufacturers. Medicare, Medicare Part D, and Medicare Advantage are registered trademarks of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these organizations.